Trials / Active Not Recruiting
Active Not RecruitingNCT06885619
Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis
Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction Though Plasma Multiomics Analysis
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Beijing Anzhen Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Detailed description
Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack sufficient predictive power for adverse outcomes. Multi-omics approaches - integrating proteomics(e.g., exosome proteomics), metabolomics, transcriptomics and lipidomics - offer a systems-level view that may uncover novel prognostic signatures.
Conditions
- Acute Myocardial Infarction (AMI)
- Left Ventricular Remodeling
- Major Adverse Cardiovascular Event
- Plasma Multi-Omics
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Diagnostic Test: echocardiography and blood collection | Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2025-03-20
- Last updated
- 2025-07-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06885619. Inclusion in this directory is not an endorsement.